



m.m

#3

Box 500

0302

Patent Application  
Attorney Docket No. PC10970AGLK

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Box SEQUENCE, Director - U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 29th day of March, 2002.

Deanna L. Miller

(Signature of person mailing)

Deanna L. Miller

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Lee Harland

APPLICATION NO.: 10/055,106

: Examiner: Unknown

FILING DATE: January 23, 2002

: Group Art Unit: Unknown

TITLE: Novel Polypeptide

Box SEQUENCE

Director - U.S. Patent and Trademark Office

Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION  
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Date:

3/29/2002

Respectfully submitted,

Gabriel L. Kleiman

Gabriel L. Kleiman

Attorney for Applicant(s)

Reg. No. 40,681

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0041



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/055,106	01/23/2002	Lee Harland	PC10970AGLK

CONFIRMATION NO. 9647

## FORMALITIES LETTER



\*OC000000007561264\*

Gregg C. Benson  
Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, CT 06340

Date Mailed: 03/01/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE